These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 22605530)
1. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
2. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
3. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463 [TBL] [Abstract][Full Text] [Related]
5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
6. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224 [TBL] [Abstract][Full Text] [Related]
8. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
9. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
10. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151 [TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099 [TBL] [Abstract][Full Text] [Related]
13. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899 [TBL] [Abstract][Full Text] [Related]
14. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486 [TBL] [Abstract][Full Text] [Related]
15. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083 [TBL] [Abstract][Full Text] [Related]
16. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419 [TBL] [Abstract][Full Text] [Related]
17. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777 [TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527 [TBL] [Abstract][Full Text] [Related]
20. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]